Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
Death Stud ; 44(7): 412-418, 2020.
Article in English | MEDLINE | ID: mdl-31204898

ABSTRACT

This study was conducted to determine the relationship between various attitudes and hope levels of cancer patients. The study was conducted in an observational and cross-sectional design with 106 cancer patients who were followed in the oncology clinic of a hospital. In the study, it was found that women had lower hope levels than men, and as age decreased, hope levels increased and as educational level increased, hope levels increased. It was found that the patients who said "I have fear/worry/anxiety and think about my family as they will be left behind" had lower total scores and subscale scores of hope. The results of the study showed that individuals with cancer had relatively higher hope levels. It was determined that the patients' thoughts about death affected their hope both directly and indirectly.


Subject(s)
Attitude to Death , Hope , Neoplasms/psychology , Adult , Age Factors , Aged , Cross-Sectional Studies , Educational Status , Female , Humans , Male , Middle Aged , Sex Factors
2.
Turk J Med Sci ; 45(2): 387-92, 2015.
Article in English | MEDLINE | ID: mdl-26084131

ABSTRACT

BACKGROUND/AIM: An opinion survey was conducted to investigate the opinions and attitudes of the Turkish population regarding cancer if they or one of their family members were to receive a diagnosis of cancer. MATERIALS AND METHODS: The opinion survey was completed by 6566 subjects and consisted of questions about the demographics of the participants and their overall opinions about cancer. The other points of the investigation asked whether they would inform relatives who had cancer about the diagnosis and whether they would prefer to be informed if they were the one with the cancer diagnosis. RESULTS: The median age of the participants was 33 years (range: 18-100) and 53.3% were male. It was found that 57.7% of the participants would prefer not to disclose a cancer diagnosis to their first-degree relatives. The diagnosis had been disclosed to relatives with cancer in 69.9% of cases. When asked about their overall opinion of cancer management, 76.5% of participants were optimistic, 16.3% were pessimistic, and 2.9% had mixed opinions. CONCLUSION: This study represents one of the largest surveys done in Turkey to identify the thoughts of healthy people about cancer and their opinion on informing their relatives about the diagnosis if the relatives have cancer. It is comparable with reports from East Europe and Asian countries.


Subject(s)
Neoplasms , Truth Disclosure , Access to Information/psychology , Adult , Attitude to Health , Data Collection , Family , Female , Humans , Male , Neoplasms/diagnosis , Neoplasms/psychology , Prognosis , Public Opinion , Turkey
3.
Asian Pac J Cancer Prev ; 16(5): 1699-705, 2015.
Article in English | MEDLINE | ID: mdl-25773812

ABSTRACT

BACKGROUND: Medication errors in oncology may cause severe clinical problems due to low therapeutic indices and high toxicity of chemotherapeutic agents. We aimed to investigate unintentional medication errors and underlying factors during chemotherapy preparation and administration based on a systematic survey conducted to reflect oncology nurses experience. MATERIALS AND METHODS: This study was conducted in 18 adult chemotherapy units with volunteer participation of 206 nurses. A survey developed by primary investigators and medication errors (MAEs) defined preventable errors during prescription of medication, ordering, preparation or administration. The survey consisted of 4 parts: demographic features of nurses; workload of chemotherapy units; errors and their estimated monthly number during chemotherapy preparation and administration; and evaluation of the possible factors responsible from ME. The survey was conducted by face to face interview and data analyses were performed with descriptive statistics. Chi-square or Fisher exact tests were used for a comparative analysis of categorical data. RESULTS: Some 83.4% of the 210 nurses reported one or more than one error during chemotherapy preparation and administration. Prescribing or ordering wrong doses by physicians (65.7%) and noncompliance with administration sequences during chemotherapy administration (50.5%) were the most common errors. The most common estimated average monthly error was not following the administration sequence of the chemotherapeutic agents (4.1 times/month, range 1-20). The most important underlying reasons for medication errors were heavy workload (49.7%) and insufficient number of staff (36.5%). CONCLUSIONS: Our findings suggest that the probability of medication error is very high during chemotherapy preparation and administration, the most common involving prescribing and ordering errors. Further studies must address the strategies to minimize medication error in chemotherapy receiving patients, determine sufficient protective measures and establishing multistep control mechanisms.


Subject(s)
Antineoplastic Agents/administration & dosage , Medication Errors/statistics & numerical data , Neoplasms/drug therapy , Nurses/statistics & numerical data , Nursing Staff, Hospital/statistics & numerical data , Adult , Antineoplastic Agents/therapeutic use , Drug Administration Schedule , Humans , Middle Aged , Pharmaceutical Preparations , Surveys and Questionnaires , Turkey , Young Adult
4.
J Oncol Pharm Pract ; 21(4): 310-2, 2015 Aug.
Article in English | MEDLINE | ID: mdl-24740972

ABSTRACT

Brain metastasis is one of the most important life-threatening conditions in patients with metastatic HER-2 positive breast cancer. A lot of conventional chemotherapeutic and antibody-based regimens used routinely in treatment of the patients with breast cancer are not effective due to blood-brain barrier. In our cases, we reported on three HER-2 positive breast cancer patients with brain metastasis who were offered a combination of weekly trastuzumab plus vinorelbine after brain metastasis. In our cases, the progression-free survival were 12, 16 and 9 months for Case 1, Case 2 and Case 3, respectively. In Case 1, there was no progression in the brain. In Case 3, we did not detect any progress but the patient died due to cerebrovascular embolic events. After local treatment, the combination of weekly trastuzumab plus vinorelbine may be an effective alternative regimen in HER-2 positive breast cancer patients with brain metastases.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Brain Neoplasms/drug therapy , Breast Neoplasms/drug therapy , Receptor, ErbB-2 , Trastuzumab/administration & dosage , Vinblastine/analogs & derivatives , Adult , Brain Neoplasms/diagnosis , Brain Neoplasms/secondary , Breast Neoplasms/diagnosis , Breast Neoplasms/genetics , Drug Administration Schedule , Female , Humans , Middle Aged , Receptor, ErbB-2/genetics , Vinblastine/administration & dosage , Vinorelbine
5.
J Oncol Pharm Pract ; 21(1): 72-3, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24154651

ABSTRACT

Capecitabine plus lapatinib combination is an effective chemotherapy regimen in patients with advanced breast cancer. Neurological adverse effects secondary to this regimen were reported rarely in literature. A woman with breast cancer presented with complaints of slurred speech while using the capecitabine and lapatinib combination. Her major complaint was slurred speech. No other radiologic or laboratory disorders were detected in the patient. Slurred speech improved one week after the capecitabine and lapatinib combination was discontinued without any further intervention.


Subject(s)
Antineoplastic Agents/adverse effects , Articulation Disorders/chemically induced , Breast Neoplasms/drug therapy , Deoxycytidine/analogs & derivatives , Fluorouracil/analogs & derivatives , Quinazolines/adverse effects , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Capecitabine , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Deoxycytidine/therapeutic use , Drug Therapy, Combination , Female , Fluorouracil/administration & dosage , Fluorouracil/adverse effects , Fluorouracil/therapeutic use , Humans , Lapatinib , Middle Aged , Quinazolines/administration & dosage , Quinazolines/therapeutic use
6.
Asian Pac J Cancer Prev ; 15(15): 6025-7, 2014.
Article in English | MEDLINE | ID: mdl-25124568

ABSTRACT

BACKGROUND: Because of the relative rarity of biliary tract cancers (BTCs), defining long term survival results is difficult. In the present study, we aimed to evaluate the survival of a series of cases in Turkey. MATERIALS AND METHODS: A totally of 47 patients with billiary tract cancer from Mersin Goverment Hospital, Acibadem Kayseri Hospital and Kayseri Training and Research Hospital were analyzed retrospectively using hospital records between 2006-2012. RESULTS: The median overall survival was 19.3±3.9 months for all patients. The median disease free and overall survivals were 24.3±5.3 and 44.1±12.9 months in patients in which radical surgery was performed , but in those with with inoperable disease they were only 5.3±1.5 and 10.7±3.2 months, respectively. CONCLUSIONS: BTCs have a poor prognosis. Surgery with a microscopic negative margin is still the only curative treatment.


Subject(s)
Biliary Tract Neoplasms/mortality , Biliary Tract Neoplasms/surgery , Aged , Biliary Tract Neoplasms/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Staging , Prognosis , Retrospective Studies , Survival Rate , Turkey
7.
Clin Genitourin Cancer ; 12(6): 447-50, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25022784

ABSTRACT

BACKGROUND: Targeted therapy has improved the survival of patients with metastatic RCC. In the present study, we evaluated whether there was an effect of cytoreductive surgery on prognosis of patients with metastatic RCC using antiangiogenic tyrosine kinase inhibitor (TKI) agents. PATIENTS AND METHODS: A total of 52 patients with metastatic RCC from Akdeniz University, Afyon Kocatepe University, and Medipol University participated in the study. All the patients had received targeted antiangiogenic therapy after interferon alfa-2b. According to previous CRN, the patients were divided into 2 groups as CRN (+) and CRN (-). RESULTS: The CRN (+) group was younger than the CRN (-) group (P < .001) and the hemoglobin levels were significantly higher in the CRN (+) group (P = .023). The median progression-free survival time from the date of starting TKIs were 8.5 and 3.0 months for the CRN (+) and CRN (-) groups, respectively (P = .104). The median overall survival was 15.1 and 5.4 months for the CRN (+) and CRN (-) groups, respectively (P = .034). CONCLUSION: We speculate that CRN is still an important part of treatment modalities in patients with metastatic RCC in modern era targeted therapy, which is currently the best systemic therapy. However, the indications of CRN might be limited to good-risk patients with metastatic RCC. Further randomized studies are warranted to clarify the necessity of CRN in patients with metastatic RCC.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/surgery , Kidney Neoplasms/drug therapy , Kidney Neoplasms/surgery , Aged , Angiogenesis Inhibitors/therapeutic use , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/secondary , Combined Modality Therapy , Cytoreduction Surgical Procedures , Disease-Free Survival , Female , Humans , Interferon alpha-2 , Interferon-alpha/therapeutic use , Kaplan-Meier Estimate , Kidney Neoplasms/mortality , Male , Middle Aged , Nephrectomy , Recombinant Proteins/therapeutic use , Retrospective Studies
8.
Med Oncol ; 31(8): 74, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24958517

ABSTRACT

In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. A total of 73 patients with MPM from Akdeniz University, Acibadem Kayseri Hospital, Kayseri Training and Research Hospital, and Erciyes University were analyzed and evaluated retrospectively as two groups: second-line gemcitabine-based chemotherapy and no second-line chemotherapy. The median OS of patients who received second-line gemcitabine-based chemotherapy was 11.3 (5.1-17.5) months, while it was 9.9 (2.1-17.7) months in the patients who did not receive chemotherapy in the second-line setting (p = 0.056). When we evaluated the survival rate at the 6th, 12th, 18th, 24th, and 36th month, the OS rate of the 36th month was significantly higher in patients who received gemcitabine-based second-line chemotherapy (p = 0.041). When evaluating the OS from diagnosis to death, the median OS values were 20.8 (17.5-24.1) months for first-line pemetrexed-based regimens then second-line gemcitabine alone and 13.1 (9.0-17.1) months supportive care after first-line pemetrexed-based regimens (p = 0.005). According to our results, we may consider gemcitabine-based regimens as second-line chemotherapy after treatment with pemetrexed plus platinum in patients with MPM.


Subject(s)
Deoxycytidine/analogs & derivatives , Lung Neoplasms/drug therapy , Lung Neoplasms/mortality , Mesothelioma/drug therapy , Mesothelioma/mortality , Aged , Antimetabolites, Antineoplastic/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/administration & dosage , Deoxycytidine/therapeutic use , Female , Glutamates/administration & dosage , Glutamates/therapeutic use , Guanine/administration & dosage , Guanine/analogs & derivatives , Guanine/therapeutic use , Humans , Lung Neoplasms/pathology , Male , Mesothelioma/pathology , Mesothelioma, Malignant , Middle Aged , Pemetrexed , Retrospective Studies , Survival Rate , Treatment Outcome , Gemcitabine
9.
Asian Pac J Cancer Prev ; 15(10): 4165-8, 2014.
Article in English | MEDLINE | ID: mdl-24935364

ABSTRACT

BACKGROUND: The prognosis of primary glioblastoma (GBM) is poor. Approximately 2/3 of primary brain tumor diagnoses are GBM, of which 95% are primary lesions. In this study, we aimed to evaluate whether more sunlight exposure has an effect on survival of patients with primary GBM. MATERIALS AND METHODS: A total of 111 patients with primary GBM were enrolled from Kayseri in inner Anatolia which has a cold climate (n: 40) and Mersin in Mediterranean region with a warm climate and more sunlight exposure (n: 71). The patients with primary GBM were divided into two groups as Kayseri and Mersin and compared for progression free survival (PFS) and overall survival (OS). RESULTS: The PFS values were 7.0 and 4.7 months for Kayseri and Mersin groups, respectively (p=0.10) and the respective OS values were 13.3 and 9.4 months (p=0.13). We did not found any significant difference regarding age, sex, comorbidity, smoking, surgery, resurgery, adjuvant chemoradiotherapy and palliative chemotherapy between the groups. CONCLUSIONS: We found that more sunlight exposure had no impact on prognosis of patients with primary GBM, adding inconsistency to the literature about the relationship between sunlight and GBM.


Subject(s)
Brain Neoplasms/mortality , Glioblastoma/mortality , Sunlight , Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Brain Neoplasms/surgery , Chemoradiotherapy, Adjuvant , Disease-Free Survival , Environmental Exposure , Female , Geography , Glioblastoma/drug therapy , Glioblastoma/surgery , Humans , Male , Middle Aged , Turkey , Vitamin D
10.
J Oncol Pharm Pract ; 20(4): 298-301, 2014 Aug.
Article in English | MEDLINE | ID: mdl-23929730

ABSTRACT

Sunitinib which is used in the treatment of kidney cancer, gastrointestinal stromal tumor, and advanced pancreatic neuroendocrine tumor is a multi-targeted tyrosine kinase inhibitor. Although sunitinib is associated with some side effects, it is generally well tolerated. In the present case, the diagnosis of gastrointestinal stromal tumor was four years ago. The patient had multiple liver metastases at the time of diagnosis. Sunitinib was initiated with a dose of 50 mg daily for four weeks and two weeks off, because of resistance of imatinib. The patient was admitted to the hospital with purpuric rash on her arms and body in the eighth week of treatment. No other disorders or drugs which may cause purpuric rash were detected in the patient. Purpuric rash disappeared two weeks after sunitinib discontinuation without any further intervention.


Subject(s)
Antineoplastic Agents/adverse effects , Exanthema/chemically induced , Indoles/adverse effects , Pyrroles/adverse effects , Aged , Antineoplastic Agents/therapeutic use , Female , Gastrointestinal Neoplasms/drug therapy , Gastrointestinal Stromal Tumors/drug therapy , Humans , Imatinib Mesylate/therapeutic use , Indoles/administration & dosage , Protein Kinase Inhibitors/adverse effects , Protein Kinase Inhibitors/therapeutic use , Pyrroles/administration & dosage , Sunitinib
11.
Chemotherapy ; 60(2): 107-111, 2014.
Article in English | MEDLINE | ID: mdl-25721008

ABSTRACT

BACKGROUND: Stage IIIB non-small cell lung cancer (NSCLC) consists of T4N2M0 and TXN3M0 NSCLC. In the present study, we aimed to evaluate the efficacy of different treatment strategies on the survival of patients with radiologically confirmed T4N2M0 NSCLC. METHODS: A total of 145 patients were evaluated in three groups according to the treatment protocol: induction chemotherapy followed by chemoradiotherapy (induction group); chemoradiotherapy (CRT group), and chemoradiotherapy followed by consolidation chemotherapy (consolidation group). The groups were compared regarding survival. RESULTS: The median progression-free survival (PFS) was 10.9, 10.8 and 17.1 months for the induction, CRT and consolidation groups, respectively (p = 0.021). The median overall survival (OS) was 17.6, 13.8 and 25.2 months for the induction, CRT and consolidation groups, respectively (p = 0.001). CONCLUSIONS: The patients with T4N2M0 NSCLC who were treated with chemoradiotherapy followed by consolidation chemotherapy had the best outcome in terms of PFS and OS.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma, Non-Small-Cell Lung/therapy , Chemoradiotherapy/methods , Choice Behavior , Consolidation Chemotherapy/methods , Lung Neoplasms/therapy , Aged , Carcinoma, Non-Small-Cell Lung/diagnosis , Combined Modality Therapy/methods , Female , Humans , Lung Neoplasms/diagnosis , Male , Middle Aged , Retrospective Studies , Treatment Outcome
12.
Med Arch ; 67(2): 104-6, 2013.
Article in English | MEDLINE | ID: mdl-24341055

ABSTRACT

BACKGROUND: Only 20% of patients with stage III NSCLC are cured by surgery. There is a disagreement among the oncologists in terms of whether which regimen (induction chemotherapy followed chemoradiotherapy, concurrent chemoradiation or concurrent chemoradiation followed consolidation chemotherapy) is best choice in inoperable LA NSCLC. OBJECTIVE: To evaluate chemotherapy timing in inoperable LA NSCLC (before, only concomitant or after curative chemotherapy). MATERIALS AND METHODS: Total of 74 consecutive patient with LA NSCLC which was inoperable due to medical condition or stage from Kayseri Research and Training Hospital were analyzed retrospectively. The patients were divided into three groups according to treatment protocols: Induction chemotherapy followed chemoradiotherapy (Ind. CTàCRT), chemoradiotherapy (CRT) and chemoradiotherapy followed consolidation chemotherapy (CRTàCons. CT). RESULTS: When evaluating progression free survival (PFS), PFS did not significantly differed among the groups (p=0,078). We found significant difference among groups (p = 0.047) in terms of overall survival. While CRTàCons. CT arm had highest mean and median survival times, Ind. CTàCRT arm had worst OS. CONCLUSIONS: CRTàCons. CT treatment modality seems preferable regimen for treatment of inoperable LA NSCLC.


Subject(s)
Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/classification , Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Aged , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Lung Neoplasms/drug therapy , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Time-to-Treatment , Turkey/epidemiology
13.
Asian Pac J Cancer Prev ; 14(6): 3743-6, 2013.
Article in English | MEDLINE | ID: mdl-23886175

ABSTRACT

BACKGROUND: Of patients with non small cell lung cancer (NSCLC), around one third are locally advanced at the time of diagnosis. Because only a proprotion of stage III patients can be cured by surgery, in order to improve the outcomes, sequential or concurrent chemoradiation, or concurrent chemoradiation with induction or consolidation is offered to the patients with locally advanced NSCLC. Today, PET combined with computerized tomography (PET-CT) is accepted as the most sensitive technique for detecting mediastinal lymph node and extracranial metastases from NSCLC. We aimed to compare PET-CT and conventional staging procedures for decisions regarding curative treatment of locally advanced NSCLC. MATERIALS AND METHODS: A total of 168 consecutive patients were included from Acibadem Kayseri Hospital, Acibadem Adana Hospital and Kayseri Research and Training Hospital in this study. RESULTS: While the median PFS was 13.0 ± 1.9 months in the PET-CT group, it was only 6.0 ± 0.9 in the others (p<0.001). The median OS values were 20.5 ± 15.6 and 11.5 ± 1.5 months, respectively (p<0.001). DISCUSSION: As a result, we found that staging with PET CT has better results in terms of survival staging. This superiority leads to survival advantage in patients with locally advanced NSCLC.


Subject(s)
Brain Neoplasms/mortality , Carcinoma, Non-Small-Cell Lung/mortality , Mediastinal Neoplasms/mortality , Positron-Emission Tomography , Tomography, X-Ray Computed , Adenocarcinoma/diagnosis , Adenocarcinoma/mortality , Adenocarcinoma/therapy , Brain Neoplasms/secondary , Brain Neoplasms/therapy , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/therapy , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/therapy , Chemoradiotherapy , Female , Follow-Up Studies , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/mortality , Lung Neoplasms/therapy , Lymph Nodes/diagnostic imaging , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Mediastinal Neoplasms/secondary , Mediastinal Neoplasms/therapy , Middle Aged , Neoplasm Staging , Prognosis , Retrospective Studies , Survival Rate
14.
Asian Pac J Cancer Prev ; 14(6): 3887-9, 2013.
Article in English | MEDLINE | ID: mdl-23886202

ABSTRACT

INTRODUCTION: Mesothelioma is a rare neoplasm arising from mesothelial surfaces with the malignant pleural mesothelioma (MPM) as the most common form. Secondline chemotherapy in MPM is still controversial and in this study we evaluated whether it is superior to best supportive care. MATERIALS AND METHODS: A total of 51 patients with MPM from Acibadem Kayseri Hospital, Kayseri Training and Research Hospital and Erciyes University were analyzed retrospectively. The patients treated with secondline chemotherapies (SLCT) were compared with those treated with best supportive care (BSC) for overall survival. RESULTS: The median overall survival (OS) for firstline chemotherapy?SLCT and firstline chemotherapy?BSC groups were 20.3 and 14.7 months respectively (p=0.079). After firstline chemotherapy the median OS for SLCT and BSC were 5.9 and 4.7 months (p=0.355). DISCUSSION: Although there was a trend for improvement in overall survival in patients treated with secondline chemotherapy, the difference was not statistically significant. Our results do not support the proposal that secondline chemotherapy could be effective in patients with MPM.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lung Neoplasms/drug therapy , Mesothelioma/drug therapy , Palliative Care , Pleural Neoplasms/drug therapy , Salvage Therapy , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Female , Follow-Up Studies , Glutamates/administration & dosage , Guanine/administration & dosage , Guanine/analogs & derivatives , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Mesothelioma/mortality , Mesothelioma/pathology , Mesothelioma, Malignant , Middle Aged , Neoplasm Staging , Pemetrexed , Platinum/administration & dosage , Pleural Neoplasms/mortality , Pleural Neoplasms/pathology , Prognosis , Retrospective Studies , Survival Rate , Gemcitabine
15.
Asian Pac J Cancer Prev ; 14(2): 743-6, 2013.
Article in English | MEDLINE | ID: mdl-23621230

ABSTRACT

BACKGROUND: Some studies have indicated an inverse relationship between cancer risk and sunlight exposure. Others have reported that the prognosis of some cancers such as prostate, colon, ovarian and non melanoma skin cancer, were affected by the season in which the cancer was diagnosed. In our study, we evaluated whether season is prognostic in Turkish patients with breast cancer. MATERIALS AND METHODS: A total of 517 patients from Kayseri Training and Research Hospital were analysed retrospectively. Patients were divided into 4 groups according to season of cancer diagnosis: winter, spring, summer and autumn. The prognostic factors for disease free survival and overall survival were investigated. RESULTS: No significant differences were found among groups regarding prognostic factors overall. Only estrogen receptor status and lymphovascular invasion were independent prognostic factors (p=0.001 and p=0.001 respectively). We found significantly differences for mean disease free survival among groups (p=0.019). Winter group had better mean DFS while summer group had worse DFS. Mean overall survival was similar in the four groups (p=0.637). CONCLUSIONS: The season is not an independent predictive factor. However, due to interaction with other factors, we think that the season of cancer diagnosis is important for cancer prognosis.


Subject(s)
Breast Neoplasms/diagnosis , Breast Neoplasms/mortality , Seasons , Disease-Free Survival , Female , Humans , Lymphatic Metastasis , Middle Aged , Receptors, Estrogen/metabolism , Retrospective Studies , Risk , Sunlight , Survival , Turkey
16.
Asian Pac J Cancer Prev ; 14(2): 801-3, 2013.
Article in English | MEDLINE | ID: mdl-23621241

ABSTRACT

UNLABELLED: INTRADUCTION: There is known to be a relationship between vitamin D level and more aggresive breast cancer subtypes, especially triple-negative breast cancer (TNBC). It was reported that sunlight exposure has an effect on the prognosis of patients with cancer, possibly related to the conversion of vitamin D to its active form with sunlight. We aimed to evaluate the effect of sunlight exposure on patients with TNBC. MATERIALS-METHODS: A total of 1,167 patients with breast cancer from two different regions of Turkey (Antalya and Kayseri, regions having different climate and sunlight exposure intensity over the year) were analysed retrospectively. The ratio of patients with TNBC was identified in those two regions. RESULTS: The ratio of patients with TNBC was 8% and 12% for Kayseri and Antalya regions, respectively, and this difference between the two groups was statistically significant (p=0.021). DISCUSSION: Sunlight exposure may be associated with more prevalent TNBC. This finding should be investigated with a prospective study.


Subject(s)
Sunlight/adverse effects , Triple Negative Breast Neoplasms/metabolism , Environmental Exposure , Female , Humans , Middle Aged , Prognosis , Retrospective Studies , Seasons , Turkey , Vitamin D/metabolism
17.
Oncol Lett ; 5(3): 773-776, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23426076

ABSTRACT

Currently, positron emission tomography with computerized tomography (PET-CT) is the most sensitive technique for detecting extracranial metastases in non-small cell lung cancer (NSCLC). It has been reported that there is a correlation between the maximal standardized uptake value (SUV(max)) of primary tumors and prognosis in patients with NSCLC. The effect of sunlight exposure on PET-CT SUV(max) value is not known. Therefore, we aimed to evaluate the effect of sunlight exposure on PET-CT SUV(max) value in patients with NSCLC. A total of 290 patients with NSCLC from two different regions of Turkey (Kayseri, n=168 and Adana, n=122) that have different climate and sunlight exposure intensity, were included in the study. Age, gender, histology of cancer, cancer stage, smoking status, comorbidity and SUV(max) of the primary tumor area at the time of staging were evaluated as prognostic factors. In the multivariate analysis, we detected that the region was the only independent factor affecting SUV(max) (P=0.019). We identified that warmer climate and more sunlight exposure significantly increases the SUV(max) value of the primary tumor area in patients with NSCLC. Further studies are warranted to clarify the issue.

18.
Asian Pac J Cancer Prev ; 14(11): 6301-4, 2013.
Article in English | MEDLINE | ID: mdl-24377521

ABSTRACT

BACKGROUND: Some epidemiological studies reported that sunlight exposure and highvitamin D levels may decrease the morbidity and mortality related to cancer. We aimed to evaluate whether sunlight exposure has an impact on survival in patients with non small cell lung cancer. MATERIALS AND METHODS: A total of 546 patients with NSCLC from two different regions (Kayseri and Adana) differing according to sunlight exposure were analysed retrospectively. RESULTS: The median overall survival (OS) rates were 11. 6 (CI: 9.50-13.6) and 15.6 months (CI: 12.4-18.8) for Kayseri and Adana, respectively, in all patients (p=0.880). CONCLUSIONS: There were no differences between groups in terms of OS. While there is strong evidence regarding inverse relationship between cancer incidence and sunlight exposure, it is still controversial whether sunlight exposure is a good prognostic factor for survival in patients with lung cancer.


Subject(s)
Carcinoma, Non-Small-Cell Lung/mortality , Lung Neoplasms/mortality , Sunlight , Carcinoma, Non-Small-Cell Lung/pathology , Female , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Prognosis , Retrospective Studies , Survival Rate , Turkey/epidemiology
19.
Acta Inform Med ; 20(4): 259-60, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23378695

ABSTRACT

Breast cancer and lung cancer are the most common tumors that metastasize to iris. The metastasis of iris was generally diagnosed on ophthalmologic examination. In this case, we reported iris metastasis of patients with adenocarcinoma of breast cancer and MRI findings. We report a case of a 51-year-old. She was diagnosed breast cancer two years ago. After adjuvant chemotherapy, radiotherapy and trastuzumab, she was admitted to hospital with the complaints of headache on February 2012. The magnetic resonance imaging (MRI ) revealed multiple brain metastasis. Whole brain radiotherapy and palliative chemotherapy were applied to the patients. In follow-up, on ophthalmological examination, there was a solid lesion on iris. The orbital MRI was performed and it revealed the thickness on iris of left eye. After diagnostic procedure final pathological rewiev reported that invasive ductal carcinom metastasis. Iris metastasis may be considered by MRI findings following: The thickness on iris and contrast enhanced lesion. This reason may be resulted that the fine niddle aspiration biopsy for diagnosis of iris metastasis is not need.

20.
Jpn J Clin Oncol ; 40(10): 989-91, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20522447

ABSTRACT

Docetaxel (Taxotere), an anticancer agent, is known to cause various reactions, including hypersensitivity, oedema, skin toxicity with erythrodysesthesia syndrome, infusion site reactions, alopecia, nail onycholysis, nail pigmentation, photosensitivity, scleroderma and stomatitis. However, of all the reported effects, photosensitivity has only rarely been described in the literature. We experienced a case of cutaneous photosensitivity with aberrations in porphyrin biosynthesis that developed 1 month after the patient received combination chemotherapy consisting of docetaxel and trastuzumab. The eruption resolved with sun avoidance and discontinuation of docetaxel therapy. To our knowledge, this is the first case of a photosensitive reaction with enhanced levels of porphyrins during docetaxel therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/drug therapy , Dermatitis, Phototoxic/etiology , Porphyrins/biosynthesis , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/pathology , Docetaxel , Exanthema/chemically induced , Female , Humans , Middle Aged , Neoplasm Metastasis , Taxoids/adverse effects , Trastuzumab
SELECTION OF CITATIONS
SEARCH DETAIL
...